Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 215135, 10 pages
http://dx.doi.org/10.1155/2015/215135
Review Article

Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

1Department of Pediatric Oncology, A. Gemelli Hospital, Catholic University of Rome, Largo A Gemelli, 1, 00168 Rome, Italy
2Anatomic Pathology, Catholic University, “A. Gemelli” Hospital, 00168 Rome, Italy

Received 26 August 2014; Accepted 4 November 2014

Academic Editor: Murat Gokden

Copyright © 2015 Daniela Rizzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Faury, A. Nantel, S. E. Dunn et al., “Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1196–1208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Broniscer and A. Gajjar, “Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist,” Oncologist, vol. 9, no. 2, pp. 197–206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. K. J. Cohen, I. F. Pollack, T. Zhou et al., “Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group,” Neuro-Oncology, vol. 13, no. 3, pp. 317–323, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. S. Lashford, P. Thiesse, A. Jouvet et al., “Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study,” Journal of Clinical Oncology, vol. 20, no. 24, pp. 4684–4691, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Broniscer, M. Chintagumpala, M. Fouladi et al., “Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children,” Journal of Neuro-Oncology, vol. 76, no. 3, pp. 313–319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Ruggiero, G. Cefalo, M. L. Garré et al., “Phase II trial of temozolomide in children with recurrent high-grade glioma,” Journal of Neuro-Oncology, vol. 77, no. 1, pp. 89–94, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. S. Nicholson, C. S. Kretschmar, M. Krailo et al., “Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group,” Cancer, vol. 110, no. 7, pp. 1542–1550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. K. J. Cohen, R. L. Heideman, T. Zhou et al., “Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group,” Neuro-Oncology, vol. 13, no. 4, pp. 410–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. A. Maher, F. B. Furnari, R. M. Bachoo et al., “Malignant glioma: genetics and biology of a grave matter,” Genes & Development, vol. 15, no. 11, pp. 1311–1333, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. B. S. Paugh, C. Qu, C. Jones et al., “Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 3061–3068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. J. MacDonald, D. Aguilera, and C. M. Kramm, “Treatment of high-grade glioma in children and adolescents,” Neuro-Oncology, vol. 13, no. 10, pp. 1049–1058, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Stupp, M. Gander, S. Leyvraz, and E. Newlands, “Current and future developments in the use of temozolomide for the treatment of brain tumours,” The Lancet Oncology, vol. 2, no. 9, pp. 552–560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Esteller, J. Garcia-Foncillas, E. Andion et al., “Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents,” The New England Journal of Medicine, vol. 343, no. 19, pp. 1350–1354, 2000. View at Google Scholar
  15. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Eoli, F. Menghi, M. G. Bruzzone et al., “Methylation of O6-methylguanine DNA methytransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival,” Clinical Cancer Research, vol. 13, no. 9, pp. 2606–2613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. I. F. Pollack, R. L. Hamilton, R. W. Sobol et al., “O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3431–3437, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Donson, S. O. Addo-Yobo, M. H. Handler, L. Gore, and N. K. Foreman, “MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma,” Pediatric Blood and Cancer, vol. 48, no. 4, pp. 403–407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. F. R. Buttarelli, M. Massimino, M. Antonelli et al., “Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas,” Child's Nervous System, vol. 26, no. 8, pp. 1051–1056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Srivastava, A. Jain, P. Jha et al., “MGMT gene promoter methylation in pediatric glioblastomas,” Child's Nervous System, vol. 26, no. 11, pp. 1613–1618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Schlosser, S. Wagner, J. M. Hlisch et al., “MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience,” Pediatric Blood & Cancer, vol. 54, no. 2, pp. 228–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Y. Lee, C.-K. Park, S.-H. Park, K.-C. Wang, B.-K. Cho, and S.-K. Kim, “MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA,” Child's Nervous System, vol. 27, no. 11, pp. 1877–1883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Shinojima, K. Tada, S. Shiraishi et al., “Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme,” Cancer Research, vol. 63, no. 20, pp. 6962–6970, 2003. View at Google Scholar · View at Scopus
  24. T. A. Libermann, H. R. Nusbaum, N. Razon et al., “Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin,” Nature, vol. 313, no. 5998, pp. 144–147, 1985. View at Publisher · View at Google Scholar · View at Scopus
  25. I. F. Pollack, R. L. Hamilton, C. D. James et al., “Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort,” Journal of Neurosurgery, vol. 105, no. 5, pp. 418–424, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Bax, N. Gaspar, S. E. Little et al., “EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines,” Clinical Cancer Research, vol. 15, pp. 5753–5761, 2009. View at Google Scholar
  27. I. K. Mellinghoff, M. Y. Wang, I. Vivanco et al., “Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors,” The New England Journal of Medicine, vol. 353, no. 19, pp. 2012–2024, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel, “PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors,” Clinical Cancer Research, vol. 13, no. 2 I, pp. 378–381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. D. Prados, K. R. Lamborn, S. Chang et al., “Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma,” Neuro-Oncology, vol. 8, no. 1, pp. 67–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. W. K. A. Yung, J. J. Vredenburgh, T. F. Cloughesy et al., “Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study,” Neuro-Oncology, vol. 12, no. 10, pp. 1061–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Broniscer, S. J. Baker, C. F. Stewart et al., “Phase Ii and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma,” Clinical Cancer Research, vol. 15, no. 2, pp. 701–707, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. I. Jakacki, M. Hamilton, R. J. Gilbertson et al., “Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children's oncology group phase I consortium study,” Journal of Clinical Oncology, vol. 26, no. 30, pp. 4921–4927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Geoerger, D. Hargrave, F. Thomas et al., “Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors,” Neuro-Oncology, vol. 13, no. 1, pp. 109–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Haas-Kogan, M. D. Prados, T. Tihan et al., “Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib,” Journal of the National Cancer Institute, vol. 97, no. 12, pp. 880–887, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M.-E. Halatsch, S. Löw, T. Hielscher, U. Schmidt, A. Unterberg, and V. I. Vougioukas, “Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib,” Anticancer Research, vol. 28, no. 6A, pp. 3725–3728, 2008. View at Google Scholar · View at Scopus
  36. D. Wang, H.-J. S. Huang, A. Kazlauskas, and W. K. Cavenee, “Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase,” Cancer Research, vol. 59, no. 7, pp. 1464–1472, 1999. View at Google Scholar · View at Scopus
  37. A. Erlandsson, M. Enarsson, and K. Forsberg-Nilsson, “Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor,” Journal of Neuroscience, vol. 21, no. 10, pp. 3483–3491, 2001. View at Google Scholar · View at Scopus
  38. N. A. Lokker, C. M. Sullivan, S. J. Hollenbach, M. A. Israel, and N. A. Giese, “Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors,” Cancer Research, vol. 62, no. 13, pp. 3729–3735, 2002. View at Google Scholar · View at Scopus
  39. M. Maxwell, S. P. Naber, H. J. Wolfe et al., “Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance,” The Journal of Clinical Investigation, vol. 86, no. 1, pp. 131–140, 1990. View at Publisher · View at Google Scholar · View at Scopus
  40. F. S. Vassbotn, A. Östman, N. Langeland et al., “Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line,” Journal of Cellular Physiology, vol. 158, no. 2, pp. 381–389, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. B. S. Paugh, A. Broniscer, C. Qu et al., “Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma,” Journal of Clinical Oncology, vol. 29, no. 30, pp. 3999–4006, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Puget, C. Philippe, D. A. Bax et al., “Mesenchymal transition and pdgfra amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas,” PLoS ONE, vol. 7, no. 2, Article ID e30313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Zarghooni, U. Bartels, E. Lee et al., “Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1337–1344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. D. A. Bax, A. Mackay, S. E. Little et al., “A distinct spectrum of copy number aberrations in pediatric high-grade gliomas,” Clinical Cancer Research, vol. 16, no. 13, pp. 3368–3377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. B. S. Paugh, X. Zhu, C. Qu et al., “Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas,” Cancer Research, vol. 73, no. 20, pp. 6219–6229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Schwartzentruber, A. Korshunov, X.-Y. Liu et al., “Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma,” Nature, vol. 482, no. 7384, pp. 226–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. F. B. Furnari, T. Fenton, R. M. Bachoo et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment,” Genes and Development, vol. 21, no. 21, pp. 2683–2710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Raymond, A. A. Brandes, C. Dittrich et al., “Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4659–4665, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Y. Wen, W. K. A. Yung, K. R. Lamborn et al., “Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American brain tumor consortium study 99–08,” Clinical Cancer Research, vol. 12, no. 16, pp. 4899–4907, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. D. A. Reardon, M. J. Egorin, J. A. Quinn et al., “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 23, pp. 9359–9368, 2005. View at Google Scholar
  51. I. F. Pollack, R. I. Jakacki, S. M. Blaney et al., “Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report,” Neuro-Oncology, vol. 9, no. 2, pp. 145–160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. J. S. Smith, I. Tachibana, S. M. Passe et al., “PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme,” Journal of the National Cancer Institute, vol. 93, no. 16, pp. 1246–1256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Raffel, L. Frederick, J. R. O'Fallon et al., “Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations,” Clinical Cancer Research, vol. 5, no. 12, pp. 4085–4090, 1999. View at Google Scholar · View at Scopus
  54. J. A. Kraus, J. Felsberg, J. C. Tonn, G. Reifenberger, and T. Pietsch, “Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood,” Neuropathology and Applied Neurobiology, vol. 28, no. 4, pp. 325–333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. I. F. Pollack, R. L. Hamilton, P. C. Burger et al., “Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group,” Journal of Neuro-Oncology, vol. 99, no. 2, pp. 155–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Oka, A. Soeda, A. Inagaki et al., “VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells,” Biochemical and Biophysical Research Communications, vol. 360, no. 3, pp. 553–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. S. P. Leon, R. D. Folkerth, and P. M. Black, “Microvessel density is a prognostic indicator for patients with astroglial brain tumors,” Cancer, vol. 77, no. 2, pp. 362–372, 1996. View at Google Scholar
  58. N. O. Schmidt, M. Westphal, C. Hagel et al., “Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis,” International Journal of Cancer, vol. 84, pp. 10–18, 1999. View at Publisher · View at Google Scholar
  59. Y.-H. Zhou, F. Tan, K. R. Hess, and W. K. A. Yung, “The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival,” Clinical Cancer Research, vol. 9, no. 9, pp. 3369–3375, 2003. View at Google Scholar · View at Scopus
  60. D. Schiff and B. Purow, “Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme: commentary,” Nature Clinical Practice Oncology, vol. 5, no. 4, pp. 186–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. M. C. Chamberlain, “Bevacizumab plus irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 1012–1013, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1253–1259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Lai, E. Filka, B. McGibbon et al., “Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability,” International Journal of Radiation Oncology, Biology, Physics, vol. 71, no. 5, pp. 1372–1380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Gururangan, S. N. Chi, T. Y. Poussaint et al., “Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 3069–3075, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Narayana, S. Kunnakkat, J. Chacko-Mathew et al., “Bevacizumab in recurrent high-grade pediatric gliomas,” Neuro-Oncology, vol. 12, no. 9, pp. 985–990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Parekh, R. Jubran, A. Erdreich-Epstein et al., “Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen,” Journal of Neuro-Oncology, vol. 103, no. 3, pp. 673–680, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. I. F. Pollack, S. D. Finkelstein, J. Burnham et al., “Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort,” Cancer Research, vol. 61, no. 20, pp. 7404–7407, 2001. View at Google Scholar · View at Scopus
  68. I. F. Pollack, S. D. Finkelstein, J. Woods et al., “Expression of p53 and prognosis in children with malignant gliomas,” The New England Journal of Medicine, vol. 346, no. 6, pp. 420–427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. J. A. Simon and R. E. Kingston, “Mechanisms of polycomb gene silencing: knowns and unknowns,” Nature Reviews Molecular Cell Biology, vol. 10, no. 10, pp. 697–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Wu, A. Broniscer, T. A. McEachron et al., “Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas,” Nature Genetics, vol. 44, no. 3, pp. 251–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Sturm, H. Witt, V. Hovestadt et al., “Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma,” Cancer Cell, vol. 22, no. 4, pp. 425–437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. D.-A. Khuong-Quang, P. Buczkowicz, P. Rakopoulos et al., “K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas,” Acta Neuropathologica, vol. 124, no. 3, pp. 439–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. G. H. Gielen, M. Gessi, J. Hammes, C. M. Kramm, A. Waha, and T. Pietsch, “H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas,” The American Journal of Clinical Pathology, vol. 139, no. 3, pp. 345–349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Dhayalan, R. Tamas, I. Bock et al., “The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9,” Human Molecular Genetics, vol. 20, no. 11, pp. 2195–2203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. C. M. Heaphy, R. F. de Wilde, Y. Jiao et al., “Altered telomeres in tumors with ATRX and DAXX mutations,” Science, vol. 333, no. 6041, article 425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Wiestler, D. Capper, T. Holland-Letz et al., “ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis,” Acta Neuropathologica, vol. 126, no. 3, pp. 443–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Zhao, Y. Lin, W. Xu et al., “Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α,” Science, vol. 324, no. 5924, pp. 261–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki, “IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas,” Clinical Cancer Research, vol. 15, no. 19, pp. 6002–6007, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling, “Analysis of the IDH1 codon 132 mutation in brain tumors,” Acta Neuropathologica, vol. 116, no. 6, pp. 597–602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 mutations in gliomas,” The New England Journal of Medicine, vol. 360, no. 8, pp. 765–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Antonelli, F. R. Buttarelli, A. Arcella et al., “Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas,” Journal of Neuro-Oncology, vol. 99, no. 2, pp. 209–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Hartmann, J. Meyer, J. Balss et al., “Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas,” Acta Neuropathologica, vol. 118, no. 4, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. I. F. Pollack, R. L. Hamilton, R. W. Sobol et al., “IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group,” Child's Nervous System, vol. 27, no. 1, pp. 87–94, 2011. View at Publisher · View at Google Scholar · View at Scopus